OTC · CIK 0001893219
ABPO Abpro Holdings, Inc.
Insider trading from SEC Form 4. Last filing Aug 7, 2025. Close $0.40 on Oct 9, 2026, +301% from the 52-week low and -94% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
5
with a Form 4 at this company
Price and insider trades, last year
ABPOOct 9, 2026 · close 0.40
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Abpro Holdings, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 41Moderate | Jin Wook (Miles) Suk CEO and Chairman buy | $20k 72,035 shares | +11% | +56% from low-98% from high | |
| 33Weak | Jin Wook (Miles) Suk CEO and Chairman buy | $4,212 16,200 shares | +12% | - | |
| 30Weak | Jin Wook (Miles) Suk CEO and Chairman buy | $1,081 4,325 shares | +3% | - | |
| 31Weak | Jin Wook (Miles) Suk CEO and Chairman buy | $11k 34,002 shares | +37% | - |
Transactions
The last 24 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 25, 2025 | Soo Young Lee director | AGrant or award Stock option (right to buy)derivative | +60,600 | $0.00 | $0 | 60,600 | Aug 7, 2025 |
| Jul 31, 2025 | Jin Wook (Miles) Suk CEO and Chairman | POpen-market purchase Common Stock, par value $0.0001 per share | +72,035 | $0.28 | $20k | 718,512 | Aug 4, 2025 |
| Jul 25, 2025 | Jin Wook (Miles) Suk CEO and Chairman | AGrant or award Common Stock, par value $0.0001 per share | +500,000 | $0.00 | $0 | 646,477 | Jul 29, 2025 |
| Jul 25, 2025 | Anthony D. Eisenberg director | AGrant or award Stock option (right to buy)derivative | +60,600 | $0.00 | $0 | 60,600 | Jul 29, 2025 |
| May 19, 2025 | Jin Wook (Miles) Suk CEO and Chairman | POpen-market purchase Common Stock, par value $0.0001 per share | +16,200 | $0.26 | $4,212 | 146,477 | May 19, 2025 |
| Apr 29, 2025 | Jin Wook (Miles) Suk CEO and Chairman | POpen-market purchase Common Stock, par value $0.0001 per share | +4,325 | $0.25 | $1,081 | 130,277 | May 1, 2025 |
| Apr 23, 2025 | Jin Wook (Miles) Suk CEO and Chairman | POpen-market purchase Common Stock, par value $0.0001 per share | +7,460 | $0.28 | $2,089 | 99,360 | Apr 25, 2025 |
| Apr 24, 2025 | Jin Wook (Miles) Suk CEO and Chairman | POpen-market purchase Common Stock, par value $0.0001 per share | +26,542 | $0.34 | $9,024 | 125,902 | Apr 25, 2025 |
| Nov 13, 2024 | Jin Wook (Miles) Suk Co-CEO & Chairman | AGrant or award Stock option (right to buy)derivativeindirect: By Biocelsus International Co. Ltd. | +613,500 | $0.00 | $0 | 613,500 | Nov 25, 2024 |
| Nov 13, 2024 | Ian Chan Chief Executive Officer | AGrant or award Common Stock, par value $0.0001 per share | +6,528,200 | $0.00 | $0 | 6,528,200 | Nov 25, 2024 |
| Nov 13, 2024 | Ian Chan Chief Executive Officer | AGrant or award Common Stock, par value $0.0001 per shareindirect: By FV Dynasty Trust | +1,137,200 | $0.00 | $0 | 1,137,200 | Nov 25, 2024 |
| Nov 13, 2024 | Ian Chan Chief Executive Officer | AGrant or award Common Stock, par value $0.0001 per shareindirect: By spouse | +987,400 | $0.00 | $0 | 987,400 | Nov 25, 2024 |
| Nov 13, 2024 | Ian Chan Chief Executive Officer | AGrant or award Stock option (right to buy)derivative | +777,100 | $0.00 | $0 | 777,100 | Nov 25, 2024 |
| Nov 13, 2024 | Ian Chan Chief Executive Officer | AGrant or award Stock option (right to buy)derivative | +787,300 | $0.00 | $0 | 787,300 | Nov 25, 2024 |
| Nov 13, 2024 | Ian Chan Chief Executive Officer | AGrant or award Stock option (right to buy)derivative | +787,300 | $0.00 | $0 | 787,300 | Nov 25, 2024 |
| Nov 13, 2024 | Ian Chan Chief Executive Officer | AGrant or award Stock option (right to buy)derivative | +577,500 | $0.00 | $0 | 577,500 | Nov 25, 2024 |
| Nov 13, 2024 | Jin Wook (Miles) Suk Co-CEO & Chairman | AGrant or award Common Stock, par value $0.0001 per share | +91,900 | $0.00 | $0 | 91,900 | Nov 15, 2024 |
| Nov 13, 2024 | Robert J. Markelewicz Jr. Chief Medical Officer | AGrant or award Stock option (right to buy)derivative | +24,300 | $0.00 | $0 | 24,300 | Nov 15, 2024 |
| Nov 13, 2024 | Robert J. Markelewicz Jr. Chief Medical Officer | AGrant or award Stock option (right to buy)derivative | +538,600 | $0.00 | $0 | 538,600 | Nov 15, 2024 |
| Nov 13, 2024 | Robert J. Markelewicz Jr. Chief Medical Officer | AGrant or award Stock option (right to buy)derivative | +29,800 | $0.00 | $0 | 29,800 | Nov 15, 2024 |
| Nov 13, 2024 | Robert J. Markelewicz Jr. Chief Medical Officer | AGrant or award Stock option (right to buy)derivative | +40,800 | $0.00 | $0 | 40,800 | Nov 15, 2024 |
| Nov 13, 2024 | Robert J. Markelewicz Jr. Chief Medical Officer | AGrant or award Stock option (right to buy)derivative | +41,700 | $0.00 | $0 | 41,700 | Nov 15, 2024 |
| Nov 13, 2024 | Robert J. Markelewicz Jr. Chief Medical Officer | AGrant or award Stock option (right to buy)derivative | +74,600 | $0.00 | $0 | 74,600 | Nov 15, 2024 |
| Nov 13, 2024 | Robert J. Markelewicz Jr. Chief Medical Officer | AGrant or award Stock option (right to buy)derivative | +10,200 | $0.00 | $0 | 10,200 | Nov 15, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Ian ChanChief Executive Officer
- Anthony D. Eisenbergdirector
- Soo Young Leedirector
- Robert J. Markelewicz Jr.Chief Medical Officer
- Jin Wook (Miles) SukCEO and Chairman
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.